Items where authors include "Rantala, J."
Up a levelArticle
Gagg, H. orcid.org/0000-0003-2763-0304, Williams, S.T., Conroy, S. et al. (9 more authors) (2023) Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12. 954. ISSN 2046-1402
Williams, S.T., Wells, G. orcid.org/0000-0002-1337-9836, Conroy, S. et al. (9 more authors) (2022) Precision oncology using ex vivo technology: a step towards individualised cancer care? Expert Reviews in Molecular Medicine, 24. e39. ISSN 1462-3994
Shen, J.Z., Qiu, Z., Wu, Q. et al. (12 more authors) (2021) FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells. Cell, 184 (2). 352-369.e23. ISSN 0092-8674
Kettunen, K., Boström, P.J., Lamminen, T. et al. (8 more authors) (2019) Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells. European Urology, 76 (4). pp. 430-434. ISSN 0302-2838
Jiao, X., Aravidis, C., Marikkannu, R. et al. (103 more authors) (2017) PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 8. pp. 102769-102782. ISSN 1949-2553
Dunning, A.M., Michailidou, K., Kuchenbaecker, K.B. et al. (245 more authors) (2016) Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics. ISSN 1061-4036
Spurdle, A.B., Couch, F.J., Parsons, M.T. et al. (195 more authors) (2014) Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 16. 3419. ISSN 1465-5411
Dao, K.-H.T., Rotelli, M.D., Brown, B.R. et al. (6 more authors) (2013) The PI3K/Akt1 pathway enhances steady-state levels of FANCL. Molecular Biology of the Cell, 24 (16). pp. 2582-2592.
Proceedings Paper
Gagg, H., Williams, S., Allen, R. orcid.org/0000-0003-2448-7987 et al. (7 more authors) (2022) F-1286: Ex vivo-led drug discovery in glioblastoma. In: Brain Tumor Research and Treatment. 6th Quadrennial Meeting of the World Federation of Neuro-oncology Societies (WFNOS 2022), 24-27 Mar 2022, Seoul, Korea. Korean Brain Tumor Society; Korea Society for Neuro-Oncology , s240.